Tivozanib: all 38 studies that test it

Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.

• Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney CancerRecruitingNCT06661720Phase 3
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaRecruitingNCT06053658Phase 2
• Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
• Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract CancersRecruitingNCT04645160Phase 1/2
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)CompletedNCT02627963Phase 3Results posted
• Tivozanib As Maintenance Therapy In GYNTerminatedNCT01972516Phase 2Results posted
• Tivozanib + Enzalutamide in Adv Prostate CancerTerminatedNCT01885949Phase 2Results posted
• Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerCompletedNCT01853644Phase 2Results posted
• Tivozanib for Recurrent GlioblastomaCompletedNCT01846871Phase 2Results posted
• Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT01835223Phase 1/2Results posted
• Phase II Trial of Tivozanib in Advanced Hepatocellular CancerTerminatedNCT01807156Phase 2Results posted
• A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue SarcomasCompletedNCT01782313Phase 2Results posted
• Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT01745367Phase 2Results posted
• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCCTerminatedNCT01673386Phase 2Results posted
• A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line TherapyCompletedNCT01478594Phase 2Results posted
• A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib ProtocolsTerminatedNCT01369433Not applicableResults posted
• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01297244Phase 2Results posted
• An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).CompletedNCT01076010Phase 3Results posted
• RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal CancerCompletedNCT01058655Phase 1/2Results posted
• A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell CarcinomaCompletedNCT01030783Phase 3Results posted
• A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell CarcinomaCompletedNCT00502307Phase 2Results posted
• RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on ImmunotherapyWithdrawnNCT07218692Phase 2
• A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular CarcinomaTerminatedNCT03970616Phase 1/2
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCCCompletedNCT03136627Phase 1/2
• Tivozanib + Gemcitabine in Metastatic RCCWithdrawnNCT01834183Phase 2
• Tivozanib Before Surgery in Treating Patients With Localized Kidney CancerWithdrawnNCT01769885Not applicable
• A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic EvaluationWithdrawnNCT01728181Phase 1/2
• A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic FunctionCompletedNCT01631097Phase 1
• A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363804Phase 1
• A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy SubjectsCompletedNCT01363778Phase 1
• A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy SubjectsCompletedNCT01316848Phase 1
• A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid TumorsCompletedNCT01306630Phase 1
• A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid TumorsCompletedNCT01210846Phase 1
• Study of KRN951 in Patients With Solid TumorsCompletedNCT00970411Phase 1
• An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00826878Phase 1
• A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast CancerCompletedNCT00717340Phase 1
• Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal CancersCompletedNCT00660153Phase 1
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00563147Phase 1

← Tivozanib overview